Lilly says retatrutide is ready to file, targeting obesity, sleep apnea and knee osteoarthritis

Eli Lilly said its investigational obesity drug retatrutide now has the clinical package needed to seek regulatory approval, after results from the TRIUMPH-2 and TRIUMPH-3 trials rounded out a set of five positive phase 3 studies. The company plans to file in the United States in the first quarter of 2027, seeking approval in obesity, obstructive sleep apnea and knee osteoarthritis pain ^[1].

The headline number from the newest study came from TRIUMPH-3, which enrolled people with severe obesity and established cardiovascular disease. In that trial, retatrutide produced 22.6 percent weight loss ^[1].

Retatrutide is not approved by the FDA or any other regulator. It remains an investigational medicine, and "ready to file" means only that the company believes it has enough data to submit an application — not that a decision has been made or that the drug will reach pharmacies on any particular date.

What the filing plan covers

The three conditions Lilly named are notable because they go beyond weight alone. Obstructive sleep apnea and knee osteoarthritis pain are both conditions that get worse with excess body weight, and both have been studied as separate indications for incretin drugs. Seeking all three at once would, if successful, give doctors more than one reason to prescribe and could matter for insurance coverage, since many US plans treat obesity drugs differently from drugs approved for a specific medical complication ^[1].

Several important details are not available in the source material for this story. The full TRIUMPH-2 results, the specific doses tested, the trial sizes, the length of treatment, the comparison groups, and the rates of side effects such as nausea, vomiting and treatment discontinuation are not reported here. Nor is there information on how retatrutide performed head-to-head against existing drugs like semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound). Those comparisons have not been described in the available source ^[1].

It is also not yet known what the 22.6 percent figure represents in practical terms — whether it is an average across all treated participants or a result at a specific dose, and at what time point it was measured. The source reports the number without that context ^[1].

Why it matters for patients

For people already using or considering a GLP-1 medicine, this is early news about a possible future option, not a change to anything available today. Retatrutide cannot be prescribed, and no US approval date exists. Even if Lilly files in the first quarter of 2027 as planned, FDA review typically takes many months after submission, and the agency can ask for more information or decline to approve ^[1].

The weight-loss figure reported in TRIUMPH-3 is high by the standards of currently marketed drugs, but it comes from a trial in a specific group: people with severe obesity who also had established cardiovascular disease ^[1]. Results in one population do not automatically carry over to others, and the raw percentage does not say anything about tolerability, how many people stayed on the drug, or how durable the loss was after stopping.

The possible sleep apnea and knee osteoarthritis indications are worth watching for a different reason. Coverage decisions in the US often hinge on the exact wording of an approved label. A drug approved for obstructive sleep apnea or for knee pain, in addition to obesity, can open doors with insurers that a weight-only label does not. Whether that plays out for retatrutide depends on what the FDA ultimately approves, which is unknown.

What happens next

• First quarter of 2027: Lilly plans to submit its US application for retatrutide ^[1].
• After filing: the FDA sets a review timeline. No target action date has been announced, and the company has not said whether it will seek priority review.
• Full data from TRIUMPH-2 and TRIUMPH-3, including safety and discontinuation rates, would normally be presented at medical meetings or published in journals. Those presentations have not been described in the available source.

Anyone weighing treatment options should discuss them with a clinician who knows their medical history.